1. Poland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Mabion S.A.

Mabion S.A.

MAB.WA
Mabion S.A.PL flagWarsaw Stock Exchange
7.24
PLN
-0.04
- -
117.02MMarket Cap
Mabion S.A.
MAB.WA
(Warsaw Stock Exchange)

Recent

price

7.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.22
0.2
0.17
- -
0.08
0.25
- -
- -
- -
- -
- -
3.66
10.15
9.38
4.27
0.97
2.33
Revenue per Share
0.07
-0.28
-0.4
-0.49
-0.44
-3.91
-4.84
-4.91
-5.26
-4.64
-4.06
0.12
1.43
2.55
-0.39
-3.87
-2.42
Basic EPS, GAAP
-0.88
-2.99
-2.54
-3.48
-2.42
-2.98
-1.32
-4.59
-2.97
-3.13
-2.81
-4.15
1.37
-2.5
1.7
-2.63
-0.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.09
-18.71
-3.15
-4.02
-4.76
-7.9
-11.87
-4.81
-5.16
-9.56
-13.63
-11.88
-9.96
-8.84
-9.23
-13.11
-10.17
Book Value per Share
3.15
417.32
34.23
65.64
5.52
4.18
0.32
-4.59
3.16
-1.68
-5.72
3.38
4.69
7.26
6.88
3.01
5.94
Tangible Book Value per Share
7
5
5
8
10
11
12
12
13
14
14
16
16
16
16
16
16
Basic Weighted Avg Shares
2
1
1
- -
1
3
- -
- -
- -
- -
- -
57
164
152
69
16
38
Sales/Revenue/Turnover
24.68
100
100
100
100
-1,627.11
- -
- -
- -
- -
- -
-12.18
16.16
45.18
-1.64
-319.62
-77.16
Operating Margin (%)
- -
1
- -
- -
- -
5
7
8
11
11
10
9
9
7
9
9
9
Depreciation Expense
- -
-1
-2
-4
-4
-43
-56
-58
-69
-64
-56
2
23
41
-6
-63
-39
Net Income, GAAP
6.85
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.29
- -
- -
- -
Effective Tax Rate (%)
30.86
-137.41
-239.77
-67,089.66
-537.47
-1,556.57
- -
- -
- -
- -
- -
3.35
14.14
27.21
-9.18
-397.37
-103.62
Profit Margin (%)
17
380
-149
-115
2
-12
-50
-110
6
-46
-93
-14
8
35
7
-31
-7
Working Capital
- -
- -
- -
- -
- -
- -
- -
4
3
4
3
2
4
3
2
11
2
LT Debt
22
2,037
182
521
56
45
4
-54
42
-22
-77
53
77
118
111
49
96
Total Equity
3.24
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
47.75
- -
- -
24.25
Return on Invested Capital (%)
184.21
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-32.32
- -
- -
-29.34
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
268
144
162

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
59
46
31
Cash, Cash Equivalents & STI
47
38
24
Accounts Receivable, Net
- -
1
- -
Inventories
8
2
3
Total Current Liabilities
41
39
38
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-184.76%
-26.6%
-56.19%
Free Cash Flow
-59.74%
-154.42%
-254.3%
Net Income, GAAP
190.04%
373.29%
888.54%
Sales/Revenue/Turnover
- -
406.03%
-77.17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34
30
1
5
69
2025
3
4
6
- -
16
2026
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.09
0.64
-1.01
- -
-0.39
2025
-0.94
-0.67
- -
- -
-3.87
2026
-0.6
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Medigene AG (MDG1.DE)
Baolingbao Biology Co.,Ltd. (002286.SZ)
Septerna Inc (SEPN)
Esperion Therapeutics, Inc. (ESPR)
UCB S.A. (UCB.BR)
Valneva SE (VLAP.PA)
Business
Mabion S.A. operates as a specialized biotechnology firm, having evolved into a comprehensive Contract Development and Manufacturing Organization (CDMO) for advanced biologics. The company delivers end-to-end GMP development and manufacturing services, concentrating on intricate biotherapeutics including monoclonal antibodies, bispecifics, Antibody-Drug Conjugates (ADCs), recombinant proteins, and vaccine antigens. From its facilities in Konstantynów Łódzki, Poland, established in 2007, Mabion supports global pharmaceutical partners across all stages, from initial cell line development and process optimization to drug substance production and sterile fill & finish. While maintaining its foundational work on proprietary therapeutic candidates like MabionCD20 and MabionHER2, the company's strategic focus is expanding its CDMO capabilities, particularly in Drug Substance manufacturing and engaging in co-development ventures. Recent alliances, such as a collaboration with NovalGen on a pioneering T-cell engager entering clinical trials for cancer immunotherapy, underscore its dedication to bringing cutting-edge treatments to market.